S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:ATNX

Athenex (ATNX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.20
$1.52
52-Week Range
N/A
Volume
1.88 million shs
Average Volume
194,316 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATNX stock logo

About Athenex Stock (NASDAQ:ATNX)

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

ATNX Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Athenex (NASDAQ: ATNX)
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Athenex files Chapter 11
Athenex Files For Chapter 11 Bankruptcy
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex Announces a Reverse Stock Split
Athenex Announces MHRA Decision on Oral Paclitaxel
See More Headlines
Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
652
Year Founded
N/A

Profitability

Net Income
$-103,430,000.00
Pretax Margin
-95.92%

Debt

Sales & Book Value

Annual Sales
$102.82 million
Book Value
($3.07) per share

Miscellaneous

Free Float
7,866,000
Market Cap
$1.76 million
Optionable
Optionable
Beta
1.36
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Yiu Nam Lau
    Chairman & Chief Executive Officer
  • Jeff Yordon
    COO & President-Athenex Pharmaceutical Division
  • Joe Annoni
    Chief Financial Officer
  • Darrel P. Cohen
    Chief Medical Officer
  • William Zuo
    President-China Operations

ATNX Stock Analysis - Frequently Asked Questions

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analyst estimates of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period in the prior year, the firm posted ($0.44) earnings per share.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

This page (NASDAQ:ATNX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners